All News

pills-14550__180_0.jpg

Gabapentin Use Rose as Restrictions Fell, Study Shows

MedPage Today

Gabapentin use jumped quickly in Michigan after the drug was removed from the state's controlled substance schedule in 2024, a cross-sectional study showed.

Read Article
notebook, tape measure and food

Obesity and Psoriatic Disease

Mason Arbabi, MD and Juliana S. Simonetti, MD

Obesity is a clinically important comorbidity in psoriasis and psoriatic arthritis. Excess adiposity contributes to systemic inflammation and cardiometabolic risk and may adversely affect disease severity and response to some systemic therapies. Intentional weight loss should be considered an adjunct to appropriate dermatologic and rheumatologic treatment.

Read Article
Pss.renal.crisis.kidney

Scleroderma-Specific Autoantibodies in Early Systemic Sclerosis

Jack Cush, MD

Prognostication is tenous in early scleroderma, especially in those with diffuse cutaneous systemic sclerosis (dcSSc). dcSSc has associated with substantial morbidity and disease-specific mortality.

Read Article
GCA.glossary.wordle

Steroid Delusions in Giant Cell Arteritis

Jack Cush, MD

A real world analysis of drug use in giant cell arteritis (GCA) patients shows that despite intending to taper patients off glucocorticoids (GC) by 24 months, 75% remained on GCs for ≥ 48 months.

Read Article
Advance growth

Endocrine Society - State of Obesity Science and Management

Jack Cush, MD

The Endocrine Society has published a scientific statement reframing obesity as a heterogeneous, chronically dysregulated fat-mass disorder, the biology of which is being tested effectively by GLP-1/GIP receptor agonists. Is this precision-medicine? We await long-term safety data, while assessing the outcomes in rheumatic and musculoskeletal disorders.

Read Article
Early RA Referral Clinics Work (9.18.2026) Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/ofGKCCNQnE https://t.co/fn0L4goAMT https://t.co/F8QKs7261x

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic: GLP-1s and History of Thyroid Cancer? Daric Mueller, PA-C, St. Clair Shores, MI, presents this case as part of RheumNow's "The Obesity Imperative" campaign, presented in September 2026. https://t.co/rhsUNVIdQ4 https://t.co/mjHEWNIGqU

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Bariatric Surgery "Curing" Arthritis? Dr. Richard Conway, Dublin, presents this QD Clinic as part of RheumNow's "The Obesity Imperative" campaign, presented in September 2026. https://t.co/YwtSkroMta https://t.co/tl8eSrvGhq

Links:

Dr. John Cush RheumNow ( View Tweet)
Obesity in Rheumatic Diseases: More than just a Comorbidity https://t.co/0QJ188HYSm https://t.co/3L09m2cowl

Links:

Dr. John Cush RheumNow ( View Tweet)
Metabolomic/proteomics w/ cardiac MRI & longitudinal outcomes in 488079 UK Biobank pts shows chronic systemic inflammation assoc w/ reduced LV volumes, incr CV risk (cytokines, GFs, IL-1, TNF as potential mediators) https://t.co/3woGOttKHz https://t.co/eJLkPyJe6U

Links:

Dr. John Cush RheumNow ( View Tweet)
Obesity and Gout: An Old Relationship with New Thoughts https://t.co/T71u9Ta4NS https://t.co/B7vUVqIBQE

Links:

Dr. John Cush RheumNow ( View Tweet)
🚨 Registration opens October 1! RheumNow Live 2027 returns January 30–31 for our 9th Annual CME Meeting. 📍 Dallas + Online 📅 January 30–31, 2027 🎓 High-impact CME. Expert faculty. Real-world rheumatology. The rheumatology meeting that sets the tone for the year ahead. https://t.co/PFZ37DlTQe
Dr. John Cush RheumNow ( View Tweet)
Systematic review 14 studies assessed Lung ultrasound (LUS) (vs HRCT) to detect RA-ILD (using threshold of ≥ 5 B-lines) found sensitivity was 86.8% (95% CI 80.1–91.4), specificity 75.4% (95% CI 62.3–85.1), and AUC 0.890 https://t.co/GlNpsPBwtS https://t.co/FJ6B5E5CWy

Links:

Dr. John Cush RheumNow ( View Tweet)
FORWARD is a Phase 4, OL trial in 51 refractory uncontrolled gout pts Rx w/ MTX plus higher doses pegloticase (16 or 30mg) IV q4wk. At 24-wk Responses similar 68% or 73%. ~31% of responders later had SUA >6. Confusing anti-Drug Ab results in this trial?? https://t.co/udjE7sXDm5 https://t.co/F8VGDAyJzb

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 119 Rheum pts on GLP-1 Rx (65% T2DM, 35% obesity; mean BMI 35). @ 12 mos wt loss −7.7 kg & 56% improved ≥1 BMI category. Signif decr in A1c, FBS, lipids, LDL, TG, ESR & CRP. GLP-1RAs useful cardiometabolic benefits https://t.co/fdNtvGu8Vb~ https://t.co/EdAqXfsjW0

Links:

Dr. John Cush RheumNow ( View Tweet)
Single center, DBRPCT of tofacitinib 11 mg/d vs PBO in 100 knee OA pts (KL Gr 1-2); At wk 12 there was NO significant differences betw groups in VAS Pain, or other outcomes-WOMAC, Oxford Knee Score, EQ-5D-5L, analgesic use https://t.co/VDtgY7hTm4 https://t.co/PveouQbI8r

Links:

Dr. John Cush RheumNow ( View Tweet)
Phenotypic cluster analysis of 134 CPPD pts from COLCHICORT & CHRONIC-CPPD European cohorts ID 4 Grps: 1) C1 monoarticular recurrent flares, older, W, ^CRP; 2) C2 monoarticular w persistent arthritis; 3) C3 polyarthritis lower CRP; 4) C4 polyarticular (spine/shoulder( & recurrent https://t.co/ghMCmDLCki
Dr. John Cush RheumNow ( View Tweet)
True or False: The TriNetX retrospective study found that JAK inhibitors significantly increased VTE risk in rheumatoid arthritis patients undergoing hip or knee replacement compared to TNF inhibitors. Check your knowledge in the latest RheumIQ quiz at https://t.co/LHFv1P6XZe.

Links:

Dr. John Cush RheumNow ( View Tweet)

CLOAK study: 3 mos DBRPCT of Colchicine vs PBO (no NSAID) in 120 symptomatic KOA (KL gr 2/3) shows no benefit in VAS pain index knee after 3 mos. (but COL pts had signif change in some biomarkers hsCRP, β-NGF (p < 0.05); PGE2, IL-1ra, IL-8, and VEGF (p < 0.16). https://t.co/MPgLpr7LPP
Dr. John Cush RheumNow ( View Tweet)
17 Sept EMA CHMP recommended marketing authorisation for secukinumab (Cosentyx) in the treatment of polymyalgia rheumatica. BUT- not yet EMA approved in the EU. https://t.co/ZGUSbw06vX https://t.co/EqRwpT8Sxo

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×